Nature Communications (Jan 2023)
Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial
- Youyi Fong,
- Yunda Huang,
- David Benkeser,
- Lindsay N. Carpp,
- Germán Áñez,
- Wayne Woo,
- Alice McGarry,
- Lisa M. Dunkle,
- Iksung Cho,
- Christopher R. Houchens,
- Karen Martins,
- Lakshmi Jayashankar,
- Flora Castellino,
- Christos J. Petropoulos,
- Andrew Leith,
- Deanne Haugaard,
- Bill Webb,
- Yiwen Lu,
- Chenchen Yu,
- Bhavesh Borate,
- Lars W. P. van der Laan,
- Nima S. Hejazi,
- April K. Randhawa,
- Michele P. Andrasik,
- James G. Kublin,
- Julia Hutter,
- Maryam Keshtkar-Jahromi,
- Tatiana H. Beresnev,
- Lawrence Corey,
- Kathleen M. Neuzil,
- Dean Follmann,
- Julie A. Ake,
- Cynthia L. Gay,
- Karen L. Kotloff,
- Richard A. Koup,
- Ruben O. Donis,
- Peter B. Gilbert,
- Immune Assays Team,
- Coronavirus Vaccine Prevention Network (CoVPN)/2019nCoV-301 Principal Investigators and Study Team,
- United States Government (USG)/CoVPN Biostatistics Team
Affiliations
- Youyi Fong
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center
- Yunda Huang
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center
- David Benkeser
- Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University
- Lindsay N. Carpp
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center
- Germán Áñez
- Novavax, Inc.
- Wayne Woo
- Novavax, Inc.
- Alice McGarry
- Novavax, Inc.
- Lisa M. Dunkle
- Novavax, Inc.
- Iksung Cho
- Novavax, Inc.
- Christopher R. Houchens
- Biomedical Advanced Research and Development Authority
- Karen Martins
- Biomedical Advanced Research and Development Authority
- Lakshmi Jayashankar
- Biomedical Advanced Research and Development Authority
- Flora Castellino
- Biomedical Advanced Research and Development Authority
- Christos J. Petropoulos
- LabCorp-Monogram Biosciences
- Andrew Leith
- Nexelis
- Deanne Haugaard
- Nexelis
- Bill Webb
- Nexelis
- Yiwen Lu
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center
- Chenchen Yu
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center
- Bhavesh Borate
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center
- Lars W. P. van der Laan
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center
- Nima S. Hejazi
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center
- April K. Randhawa
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center
- Michele P. Andrasik
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center
- James G. Kublin
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center
- Julia Hutter
- Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH
- Maryam Keshtkar-Jahromi
- Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH
- Tatiana H. Beresnev
- Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH
- Lawrence Corey
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center
- Kathleen M. Neuzil
- Center for Vaccine Development and Global Health, University of Maryland School of Medicine
- Dean Follmann
- Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Julie A. Ake
- U.S. Military HIV Research Program, Walter Reed Army Institute of Research
- Cynthia L. Gay
- University of North Carolina School of Medicine
- Karen L. Kotloff
- Center for Vaccine Development and Global Health, University of Maryland School of Medicine
- Richard A. Koup
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Ruben O. Donis
- Biomedical Advanced Research and Development Authority
- Peter B. Gilbert
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center
- Immune Assays Team
- Coronavirus Vaccine Prevention Network (CoVPN)/2019nCoV-301 Principal Investigators and Study Team
- United States Government (USG)/CoVPN Biostatistics Team
- DOI
- https://doi.org/10.1038/s41467-022-35768-3
- Journal volume & issue
-
Vol. 14,
no. 1
pp. 1 – 15
Abstract
Authors have previously reported on the efficacy and safety of the recombinant spike protein nanoparticle vaccine, NVX-CoV2373, in healthy adults. In this work, they assess anti-spike binding IgG, anti-RBD binding IgG and neutralising antibody titer as correlates of risk and protection against COVID-19.
